Nerac

Information That Drives Innovation

We’re here to help with your research needs
+1 860 872 7000
Customer Access
  • Home
  • What We Do
    • Nerac IPDex™
    • Innovation Insights and Consulting Practice
    • Regulatory
    • Medical Device and Life Sciences
    • Technology Scouting and Innovation
    • Market Research
    • Intellectual Property
    • Commercialization Services for TTOs and Start-Ups
    • Critical Updates
  • Who We Serve
  • How to Engage
  • Why Nerac?
  • Meet our Team
    • Leadership Team
    • Our Analysts
    • Our Partners
  • Nerac Insights and Publications
    • Articles
    • Case Studies
    • Press Room
    • Videos
    • Webcasts
    • White Papers
  • Contact Us
You are here: Home / Nerac Insights / Articles / Donna Mitchell-Magaldi / Clinical Literature Evaluations via an Objective Third Party Reviewer: Maintaining Compliance with the EU Medical Directives and Beyond

Clinical Literature Evaluations via an Objective Third Party Reviewer: Maintaining Compliance with the EU Medical Directives and Beyond

Facebook0
Google+0
LinkedIn0
Twitter0

By Ron Sills, Nerac Analyst, and Donna Mitchell-Magaldi, Nerac Analyst

Originally Published: September 26th, 2014

In 2009, the European Commission released MedDev 2.7.1 Rev.3 “Clinical Evaluation: A Guide for Manufacturers and Notified Bodies” as a supplement to the requirements of the EU Medical Device Directive 93/42/EEC.  In order for medical devices to be marketed in the European Union, they must be certified with a CE Mark which provides evidence of compliance to this and other applicable industry standards.  CE Marks list the registration number of the Notified Body who issued the CE Mark certification which is valid for three years.  Technical files and Design Dossiers must be kept up to date with documentation and notification of any changes to the design, manufacture or intended use of the device.  Renewal of the CE Mark is also subject to review by a Notified Body.  Since the 2009 release of MedDev 2.7 Rev. 3 supplement, manufacturers have gone through the growing pains associated with implementation of a new guideline.

In addition, the European Commission is currently working on a new regulatory framework that will be released in the next year or two with sweeping changes that will affect the clinical literature evaluation process in such a way that medical device companies would benefit from having a third party provide evaluation and analysis of the clinical literature.  It is estimated that these new rules will be in place as soon as 2014 and there will likely be no grace period if manufacturers are not in compliance once implemented.

Want to read the rest of the article? Fill out the form to download: Clinical Literature Evaluations via an Objective Third Party Reviewer: Maintaining Compliance with the EU Medical Directives and Beyond
Get Download Link

 

 

 

 

Related Posts
  • Clinical Literature Evaluations to Support Medical Device Marketing
    88
    By Roz Sweeney, Ph.D. Nerac Analyst, Uses of Clinical Literature Evaluations Comprehensive evaluations of the clinical and technical literature serve a variety of purposes for medical device companies.  Literature evaluations are frequently used in the following ways: To support design of clinical investigations (e.g. to understand expected outcomes and results for historical controls). To support regulatory…
    Tags: literature, evaluations, clinical, device, medical, read, regulatory, nerac, analyst, design
  • The Importance of Article Selection for Meeting the MedDev 2.7.1 Rev 3 Requirements
    79
    By Donna Mitchell-Magaldi, Nerac Analyst, On March 20, 2010, the revised Guideline; MedDev 2.7.1 Rev 3 Clinical Evaluation: A Guide for Manufacturers and Notified Bodies became a requirement for obtaining and maintaining a CE Mark for all classes of devices marketed in the European Union. An important component of the MedDev 2.7.1 Rev 3 is the…
    Tags: rev, meddev, evaluation, clinical, literature, device, european, commission, read, mark
  • Notified Body Audit Trends: Be in the Know!
    78
    By Donna Mitchell-Magaldi, Nerac Analyst Originally Published: February 10, 2015 It is no surprise to anyone in the medical device industry that the European Commission is working on a new regulatory framework that will in essence take the three existing directives: Directive 90/385/EEC regarding active implantable medical devices, Directive 93/42/42 regarding medical devices, and Directive…
    Tags: notified, will, bodies, body, clinical, literature, regulatory, medical, device, nerac
  • Case Studies
  • White Papers
  • Webcasts
  • Articles
    • Nerac Strategist
    • Energy
    • Food & Nutrition
    • Intellectual Property
    • Regulatory
    • Technology & Innovation
    • Medical Device & Healthcare
    • Pharmaceutical
    • Engineering
    • Market Research
    • Critical Alerts
    • Chemistry/Advanced Materials
  • Press Room

Click here to learn more about….

3d printing advanced materials aerospace Ask Kevin Videos biotech CFDA clinical literature evaluations commercialization strategies competitive intelligence conflict minerals Disruptive Technologies energy EU MDR FDA food helga weires Industry 4.0 innovation Inspiring Next intellectual property IP market analysis market research medical device medical devices nerac Nerac client questions Nerac Strategist notified body audit open innovation patenting patenting strategies patent landscape pharmaceutical Post-Market Surveillance R&D regulatory regulatory compliance Robert Beinstein Rosemarie Szostak specialty chemicals Sustainable Development Goals technology scouting Tech Scouting XcellR8
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
  • Career Opportunities
  • Privacy Policy

Copyright © 2023 Nerac · One Technology Drive · Tolland, CT 06084 · 1.860.872.7000

Sign Up for the Nerac Strategist

Like what you see? Sign up here to receive the Nerac Strategist newsletter, a compilation of analyst insights on rapidly developing industry issues, compliance challenges and commercial opportunities!

  • This field is for validation purposes and should be left unchanged.